Literature DB >> 24710959

Active injection drug-abuse offsets healthcare engagement in HIV-infected patients.

Angelike P Liappis1, Ann M Laake, Mark Delman.   

Abstract

Active injection drug use (IDU) is a behavior with the potential to offset healthcare engagement for those with HIV. At the Washington DC Veterans Affairs Medical Center, we identified 316 patients with a history of addiction during an 11-year period while actively engaged in routine visits to our HIV-primary care clinic. Among all IDU, active-abuse was determined in 141/316 (45 %). There were 120 clinically relevant blood stream infection (BSI) episodes. HIV/HCV co-infection (95 %) and use of antiretroviral therapy (76 %) were common at the time of BSI. The majority of BSIs occurred among those with active-IDU (72/120, 60 %). Active-IDU behavior was associated with more thrombotic disease (12 vs. 2 %, P = 0.001) and more frequent hospitalization (1.1/year ± 1.2 vs. 0.8/year ± 1.1, P = 0.03). When compared to drug-users with no active injection practices or those with remote IDU, active-IDU was associated with an increase in all-cause mortality (43 vs. 27 %, P = 0.003) and a decrease in age-adjusted survival (HR 1.7, CI 1.16-2.51, P = 0.007). Addressing addiction has the potential to impact avoidable medical complications and contribute to the continued, overall health of patients linked to HIV-care.

Entities:  

Mesh:

Year:  2015        PMID: 24710959     DOI: 10.1007/s10461-014-0757-4

Source DB:  PubMed          Journal:  AIDS Behav        ISSN: 1090-7165


  8 in total

1.  Experiences Using Pre-Exposure Prophylaxis for Safer Conception Among HIV Serodiscordant Heterosexual Couples in the United States.

Authors:  Angela R Bazzi; Ashley A Leech; Dea L Biancarelli; Meg Sullivan; Mari-Lynn Drainoni
Journal:  AIDS Patient Care STDS       Date:  2017-07-18       Impact factor: 5.078

2.  Racial/ethnic and HIV risk category disparities in preexposure prophylaxis discontinuation among patients in publicly funded primary care clinics.

Authors:  Hyman M Scott; Matthew Spinelli; Eric Vittinghoff; Alicia Morehead-Gee; Anne Hirozawa; Catherine James; Hali Hammer; Albert Liu; Monica Gandhi; Susan Buchbinder
Journal:  AIDS       Date:  2019-11-15       Impact factor: 4.177

Review 3.  Reducing rates of preventable HIV/AIDS-associated mortality among people living with HIV who inject drugs.

Authors:  Surita Parashar; Alexandra B Collins; Julio S G Montaner; Robert S Hogg; Michael-John Milloy
Journal:  Curr Opin HIV AIDS       Date:  2016-09       Impact factor: 4.283

4.  Mortality among blacks or African Americans with HIV infection--United States, 2008-2012.

Authors:  Azfar-e-Alam Siddiqi; Xiaohong Hu; H Irene Hall
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2015-02-06       Impact factor: 17.586

5.  HIV Infection Care and Viral Suppression Among People Who Inject Drugs, 28 U.S. Jurisdictions, 2012-2013.

Authors:  Debra L Karch; Kristen Mahle Gray; Jing Shi; H Irene Hall
Journal:  Open AIDS J       Date:  2016-06-15

6.  Healthcare Effectiveness Data and Information Set (HEDIS) measures of alcohol and drug treatment initiation and engagement among people living with the human immunodeficiency virus (HIV) and patients without an HIV diagnosis.

Authors:  Rulin C Hechter; Michael A Horberg; Constance Weisner; Cynthia I Campbell; Richard Contreras; Lie-Hong Chen; Bobbi Jo H Yarborough; Gwen T Lapham; Irina V Haller; Brian K Ahmedani; Ingrid A Binswanger; Andrea H Kline-Simon; Derek D Satre
Journal:  Subst Abus       Date:  2019-03-25       Impact factor: 3.716

7.  Long-Acting Lipoglycopeptides: "Lineless Antibiotics" for Serious Infections in Persons Who Use Drugs.

Authors:  Taylor Morrisette; Matthew A Miller; Brian T Montague; Gerard R Barber; R Brett McQueen; Martin Krsak
Journal:  Open Forum Infect Dis       Date:  2019-06-05       Impact factor: 3.835

8.  Prevalence and trends in transmitted and acquired antiretroviral drug resistance, Washington, DC, 1999-2014.

Authors:  Annette M Aldous; Amanda D Castel; David M Parenti
Journal:  BMC Res Notes       Date:  2017-09-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.